Medtech company Onward, listed on Euronext Brussels, has published its half-year report: losses remain substantial, as U.S. sales of the ARC-EX are still in their early stages, while ongoing trials and the build-out of the commercial infrastructure continue to absorb significant resources. But according to…
Francis Muyshondt03 September 2025




